St Vincent's Hospital Melbourne
I am pleased to welcome you to this Takeda-organized satellite symposium titled In It for the Long Haul: Managing the Complexity of Crohn's Disease.
The patient with Crohn's disease (CD) and their physician are in this together. They need to develop strategies and have tools available to them that help manage this chronic relapsing disease and its range of complications over the long term. The duration and complexity of the disease dictate what we strive to achieve with biologic therapy.
Remo Panaccione, MD, will focus on the necessity for long-term management in CD, which prioritizes durable clinical benefit and a good tolerability profile as the most desired characteristics of a biologic therapy. Dr Panaccione will summarize the clinical evidence and review in detail recent long-term efficacy and safety data on anti-tumor necrosis factor and gut-selective anti-integrin therapy in patients with moderate–severe CD. Treatment of complications such as fistulas and extraintestinal manifestations will also be reviewed given their impact on a patient's health-related quality of life.
Stefan Schreiber, MD, will summarize real-world experience reported to date on the use of gut-selective anti-integrin therapy and provide practical clinical insights. Patterns of use, clinical outcomes, mucosal healing, and safety experience are some of the topics that will be reviewed by Prof Schreiber.
I am confident that this symposium will be an excellent forum for discussing the long-term management of CD. On behalf of my colleagues, thank you for spending this early morning with us.